75 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Amgen (AMGN) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow https://seekingalpha.com/article/4290609-amgen-amgn-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=feed_sector_healthcare Sep 09, 2019 - The following slide deck was published by Amgen Inc. in conjunction with this event.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review http://www.zacks.com/stock/news/510923/horizons-hznp-eye-disease-drug-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-510923 Sep 10, 2019 - Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Company News For Sep 10, 2019 http://www.zacks.com/stock/news/511059/company-news-for-sep-10-2019?cid=CS-ZC--corporate_summary-511059 Sep 10, 2019 - Companies In The News Are: T,AA,AMGN,BA
Ultragenyx to Submit sBLA for Label Expansion of Crysvita http://www.zacks.com/stock/news/513339/ultragenyx-to-submit-sbla-for-label-expansion-of-crysvita?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-513339 Sep 11, 2019 - Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance http://www.zacks.com/stock/news/515058/puma-biotechs-snda-for-nerlynx-combo-gets-fda-acceptance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-515058 Sep 12, 2019 - The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study http://www.zacks.com/stock/news/520871/amgens-kyprolis-combo-improves-pfs-in-multiple-myeloma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-520871 Sep 16, 2019 - Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 http://www.zacks.com/stock/news/525940/alexion-alxn-down-on-news-of-cfo-clancys-departure-in-2019?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-525940 Sep 19, 2019 - Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
3 Big Biotech Stocks Worth Adding to Your Portfolio Now http://www.zacks.com/stock/news/527589/3-big-biotech-stocks-worth-adding-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|investment_ideas-527589 Sep 20, 2019 - We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.
5 Safe Bets for a Rocky Market http://www.zacks.com/stock/news/528232/5-safe-bets-for-a-rocky-market?cid=CS-ZC-FT-analyst_blog|investment_ideas-528232 Sep 20, 2019 - Here are 5 companies with proven track records.
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More http://www.zacks.com/stock/news/535438/biotech-stock-roundup-pipeline-updates-from-regn-biib-amgn-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-535438 Sep 25, 2019 - Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

Pages: 123456...8

Page 1>